[上海]Kite Pharma

公司官网:ww***com[点击查看] 职能类别:药品生产/质量管理

1. Conduct related daily   testing and test method development, such as endotoxin testing, TOC, Conductivity   test，HPLC test   执行日常的相关测试和检测方法的开发，如细菌内毒素检测，总有机碳，电导率测试，HPLC 测试等。
2. Familiar with related test equipment, like PTS, pH, HPLC, UV,   FTIR, HPLC   熟悉相应的测试仪器设备，如PTS、pH计、紫外、红外、气相色谱等。
3. Prepare test reports to support raw material/ product/   plant facility and other related material release.   准备支持原料、产品、厂房设施以及其他相关物料放行的相关报告。
4. Responsible for out test of raw material, package material   负责原辅料包材相关的外部测试。
5. Follow new project and strategy,   develop the new analysis methods and technology.   结合公司项目从事新的检测方法和技术的开发工作。
6. Support to conduct cleanroom routine environmental   monitoring. 协助执行洁净区域的日常环境监测。
7. Draft all QC related SOPs,   including test SOP, management SOP, and update these SOPs basing on the   validation results or trend assay results or regulation.   编写所有QC 相关的SOP，包括测试SOP,管理SOP，并根据验证结果或者趋势分析结果或法规及时更新相关SOP 。
8. Order and maintain the consumables and reagents used in QC   testing.   采购并管理测试所需的试剂耗材。
9. Operate QC equipment, cooperate   with relevant departments to conduct the equipment calibration and   maintenance timely.   使用QC相关仪器，和相关部门合作及时实施仪器的校验和维护。
10. Cooperate with other department to conduct related   validations, draft protocols, perform the procedures, analyze and report the   results. Participate in related deviation/OOS investigations. Timely review the   abnormal cases.   和其他部门合作进行相关的验证工作，编制方案，实施检测，分析并汇报结果。参与相关的偏差/OOS调查。及时回顾异常情况。

1. BS degree or above in biochemistry, chemistry or related discipline. 生物化学、化学或其他相关领域学士以上学位。
2. Ability to analyze data, troubleshoot, train and work closely with other function   具有数据分析、异常结果原因分析的能力，能够与其他部门协同工作。
3. Ability to work effectively in QC team. Good written, interpersonal and communication   skills required.   具有在QC团队高效工作的能力。良好的写作、团队合作及沟通技巧。

公司名称:Kite Pharma 公司类型:上市公司 公司介绍:"To bring about this transformation, we're developing innovative products that harness a patient's own immune system to target and attack cancer cells. In just three years, our singular focus and strategic collaborations, including multiple Cooperative Research and Development Agreements with the National Cancer Institute, have enabled us to advance an industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to address both hematological (blood-based) and solid cancers. On October 3, 2017, Kite became a Gilead company with the completion of the acquisition by Gilead Sciences. "